Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, discusses the challenges facing CAR T-cell therapy in multiple myeloma. Dr Banerjee notes that access to CAR T-cell therapy and the lengthy timeline for manufacturing may impact patient care.
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from a recent study of real-world…
Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Barry Paul, MD, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, discusses research related to idecabtagene vicleucel treatment for patients with newly diagnosed multiple myeloma and suboptimal responses…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Larry Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, Texas, discusses findings from the 5-year follow-up analysis of the KarMMa trial of idecabtagene vicleucel in patients…
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Doris Hansen, MD, Moffitt Cancer Center, Tampa, Florida, discusses an analysis of pretreatment biomarkers associated with toxicity and durable response related to idecabtagene vicleucel therapy for patients with…